A Phase III, Randomised, Double-blind, Parallel Group Study to Compare the Efficacy of AZD2171 (30 mg) in Combination with Gemcitabine and Cisplatin versus the Efficacy of Gemcitabine and Cisplatin alone in Patients with Locally Advanced or Metastatic (Stage IIIb/IV) Non Small Cell Lung Cancer.

Study identifier:D8480C00034

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase III, Randomised, Double-blind, Parallel Group Study to Compare the Efficacy of AZD2171 (30 mg) in Combination with Gemcitabine and Cisplatin versus the Efficacy of Gemcitabine and Cisplatin alone in Patients with Locally Advanced or Metastatic (Stage IIIb/IV) Non Small Cell Lung Cancer.

Medical condition

Non-small Cell Lung Cancer

Phase

Phase 3

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Interventional

Age

Date

Study Start Date: 01 Jan 1971

Primary Completion Date: -

Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

"There is no result for the study"

Documents available

Trial Results Summaries
Available here

A Phase III, Randomised, Double-blind, Parallel Group Study to Compare the Efficacy of AZD2171 (30 mg) in Combination with Gemcitabine and Cisplatin versus the Efficacy of Gemcitabine and Cisplatin alone in Patients with Locally Advanced or Metastatic (Stage IIIb/IV) Non Small Cell Lung Cancer.

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Documents available

Trial Results Summaries